Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9566448 | 0.86 | KDM4E (0.58) | RAB9AALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL6919919 | 0.84 | AGPAT2 (0.55) | RAB9AALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL8489079 | 0.82 | KDM4E (0.58) | ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL9566413 | 0.80 | HRH4 (0.66) | RAB9AALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL9464193 | 0.78 | CYP17A1 (0.61) | RAB9AALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL2855768 | 0.77 | PDGFRB (0.60) | RAB9AALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL5066542 | 0.77 | NPC1 (0.54) | RAB9AALDH1A1NPC1SMN1; SMN2KDM4E | |
| SCHEMBL19876623 | 0.76 | PDGFRB (0.55) | RAB9AALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL4777661 | 0.75 | ALDH1A1 (0.59) | RAB9AALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL182874 | 0.75 | PDGFRB (0.48) | RAB9AALDH1A1NPC1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1788875-A2 | NOVEL POLYNUCLEOTIDE SYNTHESIS LABELING CHEMISTRY | Dharmacon, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
| US-20070043051-A1 | Methods and compositions of novel triazine compounds | TIMMER RICHARD T | 2007-02-22 | — | — | US | disclosed |
| US-7173032-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. | 2007-01-04 | — | — | US | disclosed |
| WO-2006033730-A2 | NOVEL POLYNUCLEOTIDE SYNTHESIS LABELING CHEMISTRY | DHARMACON, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | RAB9A 4709/4885ALDH1A1 4407/4885NPC1 4350/4885 |
| US-20070043051-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | RAB9A 4709/4885ALDH1A1 4407/4885NPC1 4350/4885 |
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | RAB9A 4800/4885ALDH1A1 4548/4885NPC1 4764/4885 |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | RAB9A 4709/4885ALDH1A1 4407/4885NPC1 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.